Table 1 |
|||||
|
Correlation between RASSF1A promoter methylation and clinicopathological index in NPC |
|||||
|
No. of patient |
Promoter methylation status |
Frequency of methylationincidence |
|||
|
|
|||||
|
Methylated |
Unmethylated |
||||
|
|
|||||
|
Gender |
NS |
||||
|
Male |
22 |
17 |
5 |
77.27% |
|
|
Female |
16 |
10 |
6 |
62.50% |
|
|
Age |
NS |
||||
|
≤50 |
17 |
14 |
3 |
82.35% |
|
|
>50 |
21 |
13 |
8 |
61.90% |
|
|
Histological subtype |
p = 0.047 |
||||
|
poorly differentiated |
27 |
22 |
5 |
81.48% |
|
|
Well-differentiated |
11 |
5 |
6 |
45.45% |
|
|
Stage |
NS |
||||
|
I and II |
13 |
9 |
4 |
69.23% |
|
|
III and IV |
25 |
18 |
7 |
72.00% |
|
|
Lymph node |
NS |
||||
|
Positive |
29 |
22 |
7 |
75.86% |
|
|
Negative |
9 |
5 |
4 |
55.56% |
|
|
Distance metastasis |
NS |
||||
|
Positive |
5 |
4 |
1 |
80.00% |
|
|
Negative |
33 |
23 |
10 |
69.70% |
|
|
|
|||||
|
Wang et al. Journal of Experimental & Clinical Cancer Research 2009 28:160 doi:10.1186/1756-9966-28-160 |
|||||
